GLP-1 Weight Loss Medication

Dr Catrin Bevan at The London General Practice has been named among Spear’s Best Private Doctors & Surgeons for 2026, recognising her as a leading GP for high‑net‑worth individuals. A GP for over 40 years and a St Bartholomew’s graduate (1985), Dr Bevan combines extensive NHS and international experience with a proactive, preventative approach. Dr Bevan covers the full range of manages a wide range of women’s health concerns, is an expert in sleep medicine and also leads also the practice’s weight‑loss programme, overseeing the safe, appropriate prescribing of the latest GLP‑1 receptor agonists, both injectable and newly launched oral formulations, to optimise long‑term outcomes for every patient. “People are seeing success and losing weight very well, particularly when coached through how to diet and exercise by us.” Weight management is now a central focus for many of the private clinicians featured in the 2026 Spear’s list. A recent PwC report estimates that around 9% of UK adults (roughly five million people) have already used a GLP‑1 medicine, with a further 18%open to trying one. In the private sector, these drugs are increasingly embedded in structured, medically supervised programmes. Dr Catrin Bevan of The London General Practice leads the clinic’s weight‑loss service, ensuring GLP‑1 receptor agonists (both injections and new oral formulations) are prescribed safely and appropriately, particularly for menopausal women.